Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies

Advanced Drug Delivery Reviews

Volumn 27, Issue 2-3, 1997, Pages 235-256

  Pauletti, Giovanni M ^a,b   Gangwar, Sanjeev ^a,c   Siahaan, Teruna J ^a   Aubé, Jeffrey ^a   Borchardt, Ronald T ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Prolinx Inc   (United States)

Author keywords

Active and passive transport mechanisms; Efflux systems; Intestinal barrier properties; Oral peptide delivery; Peptidomimetics; Prodrugs

Indexed keywords

CELLS; ENZYME INHIBITION; METABOLISM; PHARMACOKINETICS; SUBSTRATES;

ORAL PEPTIDE BIOAVAILABILITY; PEPTIDOMIMETICS;

DRUG THERAPY;

BILE ACID; CARRIER PROTEIN; OLIGOPEPTIDE; PEPTIDE; PRODRUG;

ACTIVE TRANSPORT; CHEMICAL MODIFICATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; HUMAN; INTESTINE ABSORPTION; NONHUMAN; PASSIVE TRANSPORT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

EID: 0342437513     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00045-8     Document Type: Review

References (209)

1. Humphrey M.J., Ringrose P.S. Peptides and related drugs: a review of their absorption, metabolism and excretion. Drug Metab. Rev. 17:1986;283-310.
2. Lee V.H.L., Yamamoto A. Penetration and enzymatic barriers to peptide and protein absorption. Adv. Drug Deliv. Rev. 4:1990;171-207.
3. Bocci V. Catabolism of therapeutic proteins and peptides with implications for drug delivery. Adv. Drug Deliv. Rev. 4:1990;149-169.
4. Modi N.B. Pharmacokinetics and pharmacodynamics of recombinant proteins and peptides. J. Control. Release. 29:1994;269-281.
5. Zhou X.H. Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs. J. Control. Release. 29:1994;239-252.
6. Amidon G.L., Lee H.J. Absorption of peptide and peptidomimetic drugs. Ann. Rev. Pharmacol. Toxicol. 34:1994;321-341.
7. Pauletti G.M., Gangwar S., Knipp G.T., Nerurkar M.M., Okumu F.W., Tamura K., Siahaan T.J., Borchardt R.T. Structural requirements for intestinal absorption of peptide drugs. J. Control. Release. 41:1996;3-17.
8. D.K.F. Meijer, K. Ziegler, Mechanisms for the hepatic clearance of oligopeptides and proteins: Implications for rate of elimination, bioavailability and cell-specific drug delivery in the liver, in: K.L. Audus and T.J. Raub (Eds.), Biological Barriers to Protein Delivery, Plenum Press, New York, 1993, pp. 339-408.
9. D.L. Marks, G.J. Gores, N.F. LaRusso, Hepatic processing of peptides, in: M.D. Taylor, G.L. Amidon (Eds.), Peptide-Based Drug Design: Controlling Transport and Metabolism, American Chemical Society, Washington, DC, 1995, pp. 221-248.
10. M.J. Ruwart, Approaches to modulating liver transport of peptide drugs. in: M.D. Taylor, G.L. Amidon (Eds.), Peptide-Based Drug Design: Controlling Transport and Metabolism, American Chemical Society, Washington, DC, 1995, pp. 249-262.
11. J.L. Cleland, R. Langer (Eds.), Formulation and Delivery of Proteins and Peptides, American Chemical Society, Washington, DC, 1994.
12. D.H. Alpers, Digestion and absorption of carbohydrates and proteins, in: L.R. Johnson (Ed.), Physiology of the Gastrointestinal Tract, Raven Press, New York, 1994, pp. 1723-1750.
13. Matthews D.M. Intestinal absorption of peptides. Physiol. Rev. 55:1975;537-608.
14. Matthews D.M., Adibi S.A. Peptide absorption. Gastroenterology. 71:1976;151-161.
15. S.A. Adibi, Y.S. Kim, Peptide absorption and hydrolysis, in: L.R. Johnson (Ed.), Physiology of the Gastrointestinal Tract, Raven Press, New York, 1981, pp. 1073-1096.
16. V.H.L. Lee, R.D. Traver, M.E. Taub, Enzymatic barriers to peptide and protein drug delivery, in: V.H.L. Lee (Ed.), Peptide and Protein Drug Delivery, Marcel Dekker, New York, 1991, pp. 303-357.
17. R.H. Erickson, Peptide metabolism at brush-border membranes, in: M.D. Taylor, G.L. Amidon (Eds.), Peptide-Based Drug Design: Controlling Transport and Metabolism, American Chemical Society, Washington, DC, 1995, pp. 23-45.
18. R. Krishnamoorthy, A.K. Mitra, Peptide metabolism by gastric, pancreatic and lysosomal proteinases, in: M.D. Taylor, G.L. Amidon (Eds.), Peptide-Based Drug Design: Controlling Transport and Metabolism, American Chemical Society, Washington, DC, 1995, pp. 47-68.
19. Adibi S.A. Intestinal transport of dipeptides in man: relative importance of hydrolysis and intact absorption. J. Clin. Invest. 50:1971;2266-2275.
20. M. Cereijido, O. Ruiz, L. González-Mariscal, R.G. Contreras, M.S. Balda, M.R. García-Villegas, The paracellular pathway, in: K.L. Audus, T. Raub (Eds.), Biological Barriers to Protein Delivery, Plenum Press, New York, NY, 1993, pp. 3-21.
21. Cereijido M., Meza I., Martínez-Palomo A. Occluding junctions in cultured epithelial monolayers. Am. J. Physiol. 240:1981;C96-C102.
22. Madara J.L., Dharmsathaphorn K. Occluding junction structure-function relationships in a cultured epithelial monolayer. J. Cell Biol. 101:1985;2124-2133.
23. R.A. Conradi, P.S. Burton, R.T. Borchardt, Physico-chemical and biological factors that influence a drug's cellular permeability by passive diffusion, in: V. Pliska, B. Testa, H. Van de Waterbeemd (Eds.), Lipophilicity in Drug Action and Toxicology, VCH, Weinheim, 1996, pp. 233-250.
24. Siminoski K., Gonnella P., Bernanke J., Owen L., Neutra M.R., Murphy R.A. Uptake and transepithelial transport of nerve growth factor in suckling rat ileum. J. Cell Biol. 103:1986;1979-1990.
25. Strous G.J., Dekker J. Mucin-type glycoproteins. Crit. Rev. Biochem. Mol. Biol. 27:1992;57-92.
26. Matthews D.M., Payne J.W. Transmembrane transport of small peptides. Curr. Top. Membr. Transp. 14:1980;331-425.
27. Kim Y.S., Birtwhistle W., Kim Y.W. Peptide hydrolases in the brush-border and soluble fractions of small intestinal mucosa of rat and man. J. Clin. Invest. 51:1972;1419-1430.
28. A.J. Barrett, J.K. McDonald, Mammalian Proteases: a Glossary and Bibliography, Vol. 1, Endopeptidases, Academic Press, New York, NY, 1980.
29. J.K. McDonald, A.J. Barrett, Mammalian Proteases: a Glossary and Bibliography, Vol. 2, Exopeptidases, Academic Press, New York, NY, 1986.
30. Bai J.P.F. Comparison of distribution of brush-border exo- and endopeptidases in rat and rabbit intestine. J. Pharm. Pharmacol. 46:1994;928-930.
31. Leitch G.J. Regional variations in the composition of purified brush-borders isolated from infant and adult rabbit small intestine. Arch. Int. Physiol. Biochem. 79:1971;279-286.
32. Lindberg T. Intestinal dipeptidases: dipeptidase activity in the mucosa of the gastrointestinal tract of the adult human. Acta Physiol. Scand. 66:1966;437-443.
33. Miura S., Song S.I., Morita A., Erickson R.H., Kim Y.S. Distribution and biosynthesis of aminopeptidase N and dipeptidyl aminopeptidase IV in rat small intestine. Biochim. Biophys. Acta. 761:1983;66-75.
34. Sterchi E.E. The distribution of brush-border peptidases along the small intestine of the adult human. Pediatr. Res. 15:1981;884-885.
35. Bai J.P.F. The regional differences in the mucosal-cell lysosomal proteases within the rat small intestine. Int. J. Pharm. 107:1994;133-140.
36. Peters W.H.M., Boon C.E.W., Roelofs H.M.J., Wobbes T., Nagengast F.M., Kremers P.G. Expression of drug-metabolizing enzymes and P-170 glycoprotein in colorectal carcinoma and normal mucosa. Gastroenterology. 103:1992;448-455.
37. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. 62:1993;385-427.
38. Collington G.K., Hunter J., Allen C.N., Simmons N.L., Hirst B.H. Polarized efflux of 2′-7′-bis(2-carboxyethyl)-5(6)-carboxyfluorescein from cultured epithelium cell monolayers. Biochem. Pharmacol. 44:1992;417-424.
39. Burton P.S., Conradi R.A., Ho N.F.H. Evidence for a polarized efflux system for peptides in the apical region of Caco-2 cells. Biochem. Biophys. Res. Commun. 190:1993;760-766.
40. Wexler R.R., Greenlee W.J., Irvin J.D., Goldberg M.R., Prendergast K., Smith R.D., Timmermans P.B.M.W.M. Nonpeptide angiotensin-II receptor antagonists - The next generation in hypertensive therapy. J. Med. Chem. 39:1996;625-656.
41. Goodman M., Chorev M. On the concept of linear modified retro-peptide structures. Acc. Chem. Res. 12:1979;1-7.
42. P.S. Farmer, Bridging the gap between bioactive peptides and nonpeptides: some perspectives in design, in: E.J. Ariëns (Ed.), Drug Design, Academic Press, New York, 1980, pp. 119-143.
43. D.F. Veber, R.M. Freidinger, The design of metabolically stable peptide analogs. Trends Neurosci. (1985) 392-396.
44. Marshall G.R. A hierarchal approach to peptidomimetics. Tetrahedron. 49:1993;3547-3558.
45. Olson G.L., Bolin D.R., Bonner M.P., Bös M., Cook C.M., Fry D.C., Graves B.J., Hatada M., Hill D.E., Kahn M., Madison V.S., Rusiecki V.K., Sarabu R., Sepinwall J., Vincent G.P., Voss M.E. Concepts and progress in the development of peptide mimetics. J. Med. Chem. 36:1993;3039-3049.
46. Giannis A., Kolter T. Peptidomiments for receptor ligands - discovery, development and medical perspectives. Angew. Chem. Int. Ed. Engl. 32:1993;1244-1267.
47. Huff J.R. HIV protease - A novel chemotherapeutic target for AIDS. J. Med. Chem. 34:1991;2305-2314.
48. Ojima I., Chakravarty S., Dong Q. Antithrombic agents: from RGD to peptide mimetics. Bioorg. Med. Chem. 3:1995;337-360.
49. J.B. Kostis, E.A. DeFelice, Angiotensin Converting Enzyme Inhibitors, Alan R. Liss, New York, 1987.
50. Boger J. Renin inhibitors. Annu. Rep. Med. Chem. 20:1985;257-266.
51. Greenlee W.J. Renin inhibitors. Med. Res. Rev. 10:1990;173-236.
52. J.J. Plattner, D.W. Norbeck, Obstacles to drug development from peptide leads, in: C.R. Clark, W.H. Moos (Eds.), Drug Discovery Technologies, John Wiley and Sons, New York, 1990, pp. 92-126.
53. T.K. Sawyer, Peptidomimetic design and chemical approaches to peptide metabolism, in: M.D. Taylor, G.L. Amidon (Eds.), Peptide-Based Drug Design: Controlling Transport and Metabolism, American Chemical Society, Washington, DC, 1995, pp. 387-422.
54. J.J. Nestor, Jr., Improved duration of action of peptide drugs, in: M.D. Taylor, G.L. Amidon (Eds.), Peptide-Based Drug Design: Controlling Transport and Metabolism, American Chemical Society, Washington, DC, 1995, pp. 449-471.
55. Simon R.J., Kania R.S., Suckermann R.N., Huebner V.D., Jewell D.A., Banville S.C., Ng S., Wang L., Rosenberg S., Marlowe C.K., Spellmeyer D., Tan R., Frankel A.D., Santi D., Cohen F.E., Bartlett P.A. Peptoids - A modular approach to drug discovery. Proc. Natl. Acad. Sci. U.S.A. 39:1992;9367-9371.
56. Chorev M., Goodman M. A dozen years of retro-inverso peptidomimetics. Acc. Chem. Res. 26:1993;266-273.
57. G.D. Rose, L.M. Gierasch, J.A. Smith, Turns in peptides and proteins, in: C.B. Anfinsen, J.T. Edsall, F.M. Richards (Eds.), Advances in Protein Chemistry, Academic Press, Orlando, FL, 1985, pp. 1-109.
58. Toniolo C. Conformationally restricted peptides through short-range cyclizations. Int. J. Pept. Protein Res. 35:1990;287-300.
59. J. Aubé, Synthetic routes to lactam peptidomimetics, in: A. Abell (Ed.), Advances in Peptidomimetics. JAI Press, Greenwich, CT, 1996, in press.
60. Freidinger R.M., Veber D.F., Perlow Schwenk D., Brooks J.R., Saperstein R. Bioactive conformation of luteinizing hormone-releasing hormone: evidence from a conformationally constrained analog. Science. 210:1980;656-658.
61. Fässler A., Bold B., Capraro H.-G., Cozens R., Mestan J., Poncioni B., Rösel J., Tintelnot-Bromley M., Lang M. Aza-peptide analogs as potent human-immunodeficiency-virus type 1 protease inhibitors with oral bioavailability. J. Med. Chem. 39:1996;3203-3216.
62. J. Baker, I.J. Hidalgo, R.T. Borchardt, Intestinal epithelial and vascular endothelial barriers to peptide and protein delivery, in: V.H.L. Lee (Ed.), Peptide and Protein Drug Delivery, Marcel Dekker, New York, 1991, pp. 359-390.
63. J.L. Madara, J.S. Trier, The functional morphology of the mucosa of the small intestine, in: L.R. Johnson (Ed.), Physiology of the Gastrointestinal Tract, Raven Press, New York, 1994, pp. 1577-1622.
64. Lee V.H.L. Enzymatic barriers to peptide and protein absorption. Crit. Rev. Ther. Drug Carrier Syst. 5:1988;69-97.
65. Drewe J., Fricker G., Vonderscher J., Beglinger C. Enteral absorption of octreotide: absorption enhancement by polyoxyethylene-24-cholesterol ether. Br. J. Pharmacol. 108:1993;298-303.
66. Jaehde U., Masereeuw R., De Boer A.G., Fricker G., Nagelkerke J.F., Vonderscher J., Breimer D.D. Quantification and visualization of the transport of octreotide, a somatostatin analogue, across monolayers of cerebrovascular endothelial cells. Pharm. Res. 11:1994;442-448.
67. Lundin S., Artursson P. Absorption of a vasopressin analogue, 1-deamino-8-D-arginine-vasopressin (dDAVP), in a human intestinal epithelial cell line, Caco-2. Int. J. Pharm. 64:1990;181-186.
68. Thwaites D.T., Hirst B.H., Simmons N.L. Passive transepithelial absorption of thyrotropin-releasing hormone (THR) via a paracellular route in cultured intestinal and renal epithelial cell lines. Pharm. Res. 10:1993;674-681.
69. Adson A., Raub T.J., Burton P.S., Barsuhn C.L., Hilgers A.R., Audus K.L., Ho N.F.H. Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers. J. Pharm. Sci. 83:1994;1529-1536.
70. Pauletti G.M., Okumu F.W., Borchardt R.T. Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayers via the paracellular pathway. Pharm. Res. 14:1997;164-168.
71. Burton P.S., Hill R.B., Conradi R.A. Metabolism and transport of peptides across the intestinal mucosa. Proc. Int. Symp. Control. Rel. Bioact. Mater. 14:1987;6-7.
72. Ho N.F.H., Day J.S., Barsuhn C.L., Burton P.S., Raub T.J. Biophysical model approaches to mechanistic transepithelial studies of peptides. J. Control. Release. 11:1990;3-24.
73. Knipp G.K., Vander Velde D.G., Siahaan T.J., Borchardt R.T. The effect of solution conformation and charge on the paracellular permeability of model pentapeptides across Caco-2 cell monolayers. Pharm. Res. 12:1995;S-303.
74. Augustijns P.F., Bradshaw T.P., Gan L.-S.L., Hendren R.W., Thakker D.R. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 197:1993;360-365.
75. McMartin C., Hutchinson L.E.F., Hyde R., Peters G.E. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci. 76:1987;535-540.
76. Okumu F.W., Pauletti G.M., Vander Velde D.G., Siahaan T.J., Borchardt R.T. The effect of conformational flexibility of the permeation of model hexapeptides across monolayers of a cultured human intestinal epithelial cell (Caco-2 cells). Pharm. Res. 14:1997;169-175.
77. Knipp G.T., Ho N.F.H., Barsuhn C.L., Borchardt R.T. Delineation of paracellular diffusion in Caco-2 monolayers: Effect of perturbants on the transport of model compounds which vary in charge and size. Pharm. Res. 12:1995;S-303.
78. Pauletti G.M., Okumu F.W., Vander Velde D.G., Borchardt R.T. The effect of charge and conformational flexibility on the pathway of permeation of model hexapeptides across Caco-2 cell monolayers in unperturbed and perturbed states. Pharm. Res. 13:1996;S-235.
79. Hochman J., Artursson P. Mechanisms of absorption enhancement and tight junction regulation. J. Control. Release. 29:1994;253-267.
80. Pappenheimer J.R., Reiss K.Z. Contribution of solvent drag through intercellular junctions to absorption of nutrients by the small intestine of the rat. J. Membr. Biol. 100:1987;123-136.
81. Rojanasakul Y., Wang L.-Y., Bhat M., Glover D.D., Malanga C.J., Ma J.K.H. The transport barrier of epithelia: a comparative study on membrane permeability and charge selectivity in the rabbit. Pharm. Res. 9:1992;1029-1034.
82. Madara J.L., Barenberg D., Carlson S.L. Effects of cytochalasin D on occluding junctions of intestinal absorptive cells: further evidence that the cytoskeleton may influence paracellular permeability and junctional charge selectivity. J. Cell Biol. 102:1986;2125-2136.
83. L. Gonzáles-Mariscal, The relationship between structure and function of tight junctions, in: M. Cereijido (Ed.), Tight Junctions, CRC Press, Boca Raton, FL, 1993, pp. 67-76.
84. Rubas W., Cromwell M., Gadek T., Narindray D., Mrsny R. Structural elements which govern the resistance of intestinal tissues to compound transport. Mat. Res. Soc. Symp. Proc. 331:1994;179-185.
85. Singer S.J., Nicholson G.L. The fluid mosaic model of the structure of cell membranes. Science. 175:1972;720-731.
86. P. Yeagle, (Ed.), The Structure of Biological Membranes. CRC Press, Boca Raton, FL, 1992.
87. Conradi R.A., Hilgers A.R., Ho N.F.H., Burton P.S. The influence of peptide structure on transport across Caco-2 cells. Pharm. Res. 8:1991;1453-1460.
88. Hansch C., Fujita T. ρ, σ, π Analysis. A method for the correlation of biological activity and chemical structure. J. Am. Chem. Soc. 86:1964;1616-1626.
89. S. Ohki, R.A. Spangler, Passive and facilitated transport, in: P. Yeagle (Ed.), The Structure of Biological Membranes, CRC Press, Boca Raton, FL, 1992, pp. 655-720.
90. Smith R.N., Hansch C., Ames M.M. Selection of a reference partitioning system for drug design work. J. Pharm. Sci. 64:1975;599-606.
91. Leo A., Hansch C., Elkins D. Partition coefficients and their uses. Chem. Rev. 71:1971;525-616.
92. V. Austel, E. Kutter, Absorption, distribution and metabolism of drugs, in: J.G. Topliss (Ed.), Quantitative Structure-Activity Relationships of Drugs, Academic Press, New York, 1983, pp. 437-496.
93. Conradi R.A., Hilgers A.R., Ho N.F.H., Burton P.S. The influence of peptide structure on transport across Caco-2 cells. II. Peptide bond modification which results in improved permeability. Pharm. Res. 9:1992;435-439.
94. Kim D.C., Burton P.S., Borchardt R.T. A correlation between the permeability characteristics of a series of peptides using an in vitro cell culture model (Caco-2) and those using an in situ perfused rat ileum model of the intestinal mucosa. Pharm. Res. 10:1993;1710-1714.
95. Roseman M.A. Hydrophobicity of the peptide C=O-H-N hydrogen-bonded group. J. Membr. Biol. 201:1988;621-623.
96. Banks W.A., Kastin A.J., Coy D.H., Angulo E. Entry of DSIP peptides into dog CSF: Role of physicochemical and pharmacokinetic parameters. Brain Res. Bull. 17:1986;155-158.
97. Raessi S., Audus K.L. In vitro characterization of blood-brain barrier permeability to delta sleep-inducing peptide. J. Pharm. Pharmacol. 41:1989;848-852.
98. Gray R.A., Vander Velde D.G., Burke C.J., Manning M.C., Middaugh C.R., Borchardt R.T. Delta-sleep-inducing peptide: solution conformation studies of a membrane-permeable peptide. Biochemistry. 33:1994;1323-1331.
99. Conradi R.A., Hilgers A.R., Burton P.S., Hester J. Epithelial cell permeability of a series of peptidic HIV protease inhibitors: Amino terminal substituent effects. J. Drug Target. 2:1994;167-171.
100. Carrupt P.-A., Testa B., Bechalany A., El Tayar N., Descas P., Perrissoud D. Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. J. Med. Chem. 34:1991;1272-1275.
101. El Tayar N., Mark A.E., Vallat P., Brunne R.M., Testa B., Van Gunsteren W.F. Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: Evidence from partition coefficients and molecular dynamics simulations. J. Med. Chem. 36:1993;3757-3764.
102. Kaiser E.T., Kézdy F.J. Amphiphilic secondary structure: Design of peptide hormones. Science. 223:1984;249-255.
103. Sargent D.F., Schwyzer R. Membrane lipid phase as catalyst for peptide-receptor interaction. Proc. Natl. Acad. Sci. U.S.A. 83:1986;5774-5778.
104. Holland D.R., Quay J.F. Intestinal secretion of erythromycin base. J. Pharm. Sci. 65:1976;417-419.
105. George C.F., Gruchy B.S. Elimination of drugs by active intestinal transport. J. Pharm. Pharmacol. 31:1979;643-644.
106. Lauterbach F. Absorption of cardiac glycosides. Acta Pharmacol. Toxicol. 29(4):1971;80.
107. Lauterbach F. Resorption und sekretion von arzneistoffen durch die mucosaepithelien des gastrointestinaltraktes. Arzneim.-Forsch. Drug Res. 25:1975;479-488.
108. Beck W.T. The cell biology of multiple drug resistance. Biochem. Pharmacol. 36:1987;2879-2887.
109. Simon S.M., Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc. Natl. Acad. Sci. U.S.A. 91:1994;3497-3504.
110. Ueda K., Cardarelli C., Gottesman M.M., Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicine, and vinblastine. Proc. Natl. Acad. Sci. U.S.A. 84:1987;3004-3008.
111. Griffiths N.M., Hirst B.H., Simmons N.L. Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell layers. Br. J. Pharmacol. 108:1993;575-576.
112. Burton P.S., Conradi R.A., Hilgers A.R., Ho N.F.H. Polarized efflux pathways for peptides in Caco-2 cells: evidence for at least two distinct systems. Pharm. Res. 11:1994;S-252.
113. Burton P.S., Goodwin J.T., Conradi R.A., Ho N.F.H., Hilgers A.R. In vitro permeability of peptidomimetic drugs: The role of polarized efflux pathways as additional barriers to absorption. Adv. Drug Deliv. Rev. 23:1996;143-156.
114. Burton P.S., Conradi R.A., Ho N.F.H., Hilgers A.R., Borchardt R.T. How structural features influence the biomembrane permeability of peptides. J. Pharm. Sci. 85:1996;1336-1340.
115. Nogae I., Kohno K., Kikuchi J., Kuwano M., Akiyama S., Kiue A., Suzuki K., Yoshida Y., Kornwell M.M., Pastan I., Gottesman M.M. Analysis of structural features of dihydropyridine analogues needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein. Biochem. Pharmacol. 38:1989;519-527.
116. Zamora J.M., Pearce H.L., Beck W.T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 33:1988;454-462.
117. Sharma R.C., Inoue S., Roitelman J., Schimke R.T., Simoni R.D. Peptide transport by multidrug resistance pump. J. Biol. Chem. 267:1991;5731-5734.
118. Chen A.Y., Yu C., Potmesil M., Wall M.E., Wani M.C., Liu L.F. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res. 51:1991;6039-6044.
119. Boesch D., Muller K., Pourtier-Manzanedo A., Loor F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC833, a non-immunosuppressive cyclosporin derivative. Exp. Cell Res. 196:1991;26-32.
120. Boesch D., Gaveriaux C., Jachez B., Pourtier-Manzanedo A., Bollinger P., Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC833. Cancer Res. 51:1991;4226-4233.
121. Dantzig A.H., Shepard R.L., Cao J., Law K.L., Ehlhardt W.J., Baughman T.M., Bumol T.F., Starling J.J. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 56:1996;4171-4179.
122. Nerurkar M.M., Burton P.S., Borchardt R.T. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13:1996;528-534.
123. Nerurkar M.M., Burton P.S., Ho N.F.H., Borchardt R.T. Use of surfactants to enhance the intestinal permeability of peptides by inhibition of an apically polarized efflux system. Pharm. Res. 12:1995;S-303.
124. Burton P.S., Conradi R.A., Hilgers A.R. (B) Mechanisms of peptide and protein absorption. (2) Transcellular mechanism of peptide and protein absorption: passive aspects. Adv. Drug Deliv. Rev. 7:1991;365-386.
125. Burton P.S., Conradi R.A., Hilgers A.R., Ho N.F.H., Maggiora L.L. The relationship between peptide structure and transport across epithelial cell monolayers. J. Control. Release. 19:1992;87-98.
126. Conradi R.A., Wilkinson K.F., Rush B.D., Hilgers A.R., Ruwart M.J., Burton P.S. In vitro/in vivo models for peptide oral absorption: comparison of Caco-2 cell permeability with rat intestinal absorption of renin inhibitory peptides. Pharm. Res. 10:1993;1790-1792.
127. V.H.L. Lee, S. Dodda-Kashi, G.M. Grass, W. Rubas, Oral route of peptide and protein delivery, in: V.H.L. Lee (Eds.), Peptide and Protein Drug Delivery, Marcel Dekker, New York, 1991, pp. 691-738.
128. Amsberry K.L., Borchardt R.T. The lactonization of 2′-hydroxyhydrocinnamic acid amides: a potential prodrug for amines. J. Org. Chem. 55:1990;5867-5877.
129. Amsberry K.L., Gerstenberger A.E., Borchardt R.T. Amine prodrugs which utilize hydroxy amide lactonization. II. A potential esterase-sensitive amide prodrug. Pharm. Res. 8:1991;455-461.
130. H. Bundgaard, Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities, in: H. Bundgaard (Ed.), Design of Prodrugs, Elsevier, Amsterdam, 1985, pp. 1-92.
131. Bundgaard H. The double prodrug concept and its applications. Adv. Drug Deliv. Rev. 3:1989;39-65.
132. Bundgaard H., Møss J. Prodrugs of peptides. 7. Transdermal delivery of thyrotropin-releasing hormone (TRH) via prodrug. Int. J. Pharm. 66:1990;39-45.
133. Bundgaard H., Møss J. Prodrugs of peptides. 6. Bioreversible derivatives of thyrotropin-releasing hormone (TRH) with increased lipophilicity and resistance to cleavage by the TRH-specific serum enzyme. Pharm. Res. 7:1990;885-892.
134. Bundgaard H., Rasmussen G.J. Prodrugs of peptides. 11. Chemical and enzymatic hydrolysis kinetics of N-acyloxymethyl derivatives of a peptide-like bond. Pharm. Res. 8:1991;1238-1242.
135. Bundgaard H. Prodrugs as a means to improve the delivery of peptide drugs. Adv. Drug Deliv. Rev. 8:1992;1-38.
136. Jensen E., Bundgaard H. Aminomethylbenzoate esters of chloramphenicol as a novel prodrug type for parenteral administration. Int. J. Pharm. 70:1991;137-146.
137. Pitman I.H. Pro-drugs of amides, imides and amines. Med. Res. Rev. 1:1981;187-212.
138. Stella V.J., Charman W.N.A., Naringrekar V.H. Prodrugs: Do they have advantages in clinical practice? Drugs. 29:1985;455-473.
139. Oliyai R., Stella V.J. Prodrugs of peptides and proteins for improved formulation and delivery. Ann. Rev. Pharmacol. Toxicol. 32:1993;521-544.
140. Oliyai R. Prodrugs of peptides and peptidomimetics for improved formulation and delivery. Adv. Drug Deliv. Rev. 19:1996;275-286.
141. Weller T., Alig L., Beresini M., Blackburn B., Bunting S., Hadvary P., Muller M.H., Knopp D., Levet-Trafit B., Lipari M.T., Modi N.B., Müller M., Refino C.J., Schmitt M., Schönholzer P., Weiss S., Steiner B. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J. Med. Chem. 39:1996;3139-3147.
142. Kim J.S., Oberle R.L., Krummel D.A., Dressman J.B., Fleisher D. Absorption of ACE inhibitors from small intestine and colon. J. Pharm. Sci. 83:1994;1350-1356.
143. Kahns A.H., Buur A., Bundgaard H. Prodrugs of peptides. 18. Synthesis and evaluation of various esters of desmopressin (dDAVP). Pharm. Res. 10:1993;68-74.
144. Cook C.S., Karabatsos P.J., Schoenhard G.L., Karim A. Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334. Pharm. Res. 12:1995;1158-1164.
145. Gangwar S., Pauletti G.M., Siahaan T.J., Stella V.J., Borchardt R.T. Synthesis of a novel enzyme-sensitive cyclic prodrug of a hexapeptide using an acyloxyalkoxy promoiety. J. Org. Chem. 62:1997;1356-1362.
146. Wang B., Gangwar S., Pauletti G.M., Siahaan T.J., Borchardt R.T. Synthesis of a novel esterase-sensitive cyclic prodrug system for peptides that utilizes a "trimethyl lock"-facilitated lactonization reaction. J. Org. Chem. 62:1997;1363-1367.
147. Pauletti G.M., Gangwar S., Okumu F.W., Siahaan T.J., Stella V.J., Borchardt R.T. Esterase-sensitive cyclic prodrugs of peptides: Evaluation of an acyloxyalkoxy promoiety in a model hexapeptide. Pharm. Res. 13:1996;1615-1623.
148. Pauletti G.M., Gangwar S., Wang B., Borchardt R.T. Esterase-sensitive cyclic prodrugs of peptides: Evaluation of a phenylpropionic acid promoiety in a model hexapeptide. Pharm. Res. 14:1997;11-17.
149. Alexander J., Fromtling R.A., Bland J.A., Pelak B.A., Gilfillan E.C. (Acyloxy)alkyl carbamate prodrugs of norfloxacin. J. Med. Chem. 34:1991;78-81.
150. M. Folkmann, F.J. Lund, Acyloxymethyl carbonochloridates. New Intermediates in prodrug synthesis. Synthesis (1990) 1159-1166.
151. Gogate U.S., Repta A.J., Alexander J. N-(Acyloxyalkoxycarbonyl) derivatives as potential prodrugs of amines. I. Kinetics and mechanism of degradation in aqueous solutions. Int. J. Pharm. 40:1987;235-248.
152. Gangwar S., Jois S.D.S., Siahaan T.J., Vander Velde D.G., Stella V.J., Borchardt R.T. Structural analysis of the cyclic acyloxyalkoxycarbamate prodrug of a model hexapeptide. Pharm. Res. 13:1996;1655-1660.
153. Gochoco C.H., Ryan F.M., Miller J., Smith P.L., Hidalgo I.J. Uptake and transepithelial transport of an orally absorbed cephalosporin, cephalexin, in the human intestinal cell line, Caco-2. Int. J. Pharm. 104:1994;187-202.
154. Ganapathy V., Leibach F.H. Is intestinal peptide transport energized by a proton gradient? Am. J. Physiol. 249:1985;G153-G160.
155. Dantzig A.H., Bergin L. Carrier-mediated uptake of cephalexin in human intestinal cells. Biochem. Biophys. Res. Commun. 155:1988;1082-1087.
156. Hidalgo I.J., Ryan F.M., Marks G.J., Smith P.L. pH-dependent transepithelial transport of cephalexin in rabbit intestinal mucosa. Int. J. Pharm. 98:1993;83-92.
157. Hu M., Amidon G.L. Passive and carrier-mediated intestinal absorption components of captopril. J. Pharm. Sci. 77:1988;1007-1011.
158. Kramer W., Girbig F., Gutjahr U., Kleemann H.W., Leipe I., Urbach H., Wagner A. Interaction of renin inhibitors with the intestinal uptake system for oligopeptides and β-lactam antibiotics. Biochim. Biophys. Acta. 1027:1990;25-30.
159. Walter E., Kissel T., Reers M., Dickneite G., Hoffmann D., Stüber W. Transepithelial transport properties of peptidomimetic thrombin inhibitors in monolayers of a human intestinal cell line (Caco-2) and their correlation to in vivo data. Pharm. Res. 12:1995;360-365.
160. Dyer J., Beechey R.B., Gorvel J.P., Smith R.T., Wootton R., Shirazi-Beechey S.P. Glycyl-L-proline transport in rabbit enterocyte basolateral-membrane vesicles. Biochem. J. 269:1990;565-571.
161. Tamura K., Bhatnagar P.K., Takata J.S., Lee C.P., Smith P.L., Borchardt R.T. Metabolism, uptake, and transepithelial transport of the diastereomers of Val-Val in the human intestinal cell line, Caco-2. Pharm. Res. 13:1996;1213-1218.
162. Dantzig A.H., Hoskins J., Tabas L.B., Bright S., Shepard R.L., Jenkins I.L., Duckworth D.C., Sportsman J.R., Mackensen D., Rosteck P.R. Jr., Skatrud P.L. Association of intestinal peptide transport with a protein related to the cadherin superfamily. Science. 264:1994;430-433.
163. Abe M., Hoshi T., Tajima A. Characteristics of transmural potential changes associated with proton-peptide cotransport in toad small intestine. J. Physiol. 494:1987;481-499.
164. Muranushi N., Yoshikawa T., Yoshida M., Oguma T., Hirano K., Yamada H. Transport characteristics of ceftibuten, a new oral cephem, in rat intestinal brush-border membrane vesicles: Relation to oligopeptide and amino β-lactam transport. Pharm. Res. 6:1989;308-312.
165. Muranushi N., Horie K., Masuda K., Hirano K. Characteristics of ceftibuten uptake in Caco-2 cells. Pharm. Res. 11:1994;1761-1765.
166. Tsuji A., Tamai I. Carrier-mediated intestinal transport of drugs. Pharm. Res. 13:1996;963-977.
167. +/peptide cotransporter. Cloning, functional expression, and chromosomal localization. J. Biol. Chem. 270:1995;6456-6463.
168. Fei Y.J., Kanai Y., Nussberger S., Ganapathy V., Leibach F.H., Romero M.F., Singh S.K., Boron W.F., Hediger M.A. Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature. 368:1994;563-566.
169. Miyamoto K., Shiraga T., Yamamoto H., Haga H., Taketani Y., Morita K., Tamai I., Sai Y., Tsuji A., Takeda E. Sequence, tissue distribution and developmental changes in rat intestinal oligopeptide transporter. Biochim. Biophys. Acta. 1305:1996;34-38.
170. Walter E., Kissel T., Amidon G.L. The intestinal peptide carrier: A potential transport system for small peptide derived drugs. Adv. Drug Deliv. Rev. 20:1996;33-58.
171. Miyazaki K., Iseki K., Arita T. Intestinal absorption of several β-lactam antibiotics: IV. Binding to the various components in the intestinal mucosa of rat and role in absorption process. J. Pharmacobiodyn. 5:1982;593-602.
172. Ryan F.M., Smith P.L. Effect of altering fluid transport on the absorption of benzylpenicillin and mannitol across rat intestinal mucosa in vitro. Pharm. Res. 6:1989;S-88.
173. Kramer W., Girbig F., Gutjahr U., Kowalewski S., Adam F., Schiebler W. Intestinal absorption of β-lactam antibiotics and oligopeptides. Functional and stereospecific reconstitution of the oligopeptide transport system from rabbit small intestine. Eur. J. Biochem. 204:1992;923-930.
174. Hidalgo I.J., Bhatnagar P., Lee C.P., Smith P.L. Structural specificity for uptake via the di-/tripeptide transporter in Caco-2 cells. Pharm. Res. 10:1993;S-181.
175. Hidalgo I.J., Bhatnagar P., Lee C.P., Miller J., Cucullino G., Smith P.L. Structural requirements for interaction with the oligopeptide transporter in Caco-2 cells. Pharm. Res. 12:1995;317-319.
176. Wootton R., Hazelwood R. Relative affinity of a series of charged dipeptides for the peptide carrier of rabbit intestinal brush-border membranes. Biochem. Soc. Trans. 17:1989;691-692.
177. Wood C., Miller J., Wilson G., Hidalgo I.J. Effect of charge on affinity for the intestinal di-/tripeptide transporter. Pharm. Res. 9:1992;S-254.
178. Tamura K., Lee C.P., Smith P.L., Borchardt R.T. Effect of charge on oligopeptide transporter-mediated permeation of cyclic dipeptides across Caco-2 cell monolayers. Pharm. Res. 13:1996;1752-1754.
179. Bronk J.R., Lister N., Helliwell P.A. Stereoselectivity of dipeptide transport in rat small intestine, in vitro. J. Physiol. 467:1993;189P.
180. Tamura K., Lee C.P., Smith P.L., Borchardt R.T. Metabolism, uptake and transepithelial transport of the stereoisomers of Val-Val-Val in the human intestinal cell line, Caco-2. Pharm. Res. 13:1996;1663-1667.
181. Iseki K., Sugawara M., Saitoh H., Miyazaki K., Arita T. Comparison of transport characteristics of amino β-lactam antibiotics and dipeptides across rat intestinal brush border membrane. J. Pharm. Pharmacol. 41:1989;628-632.
182. +-coupled transport of p.o. cephalosporins via dipeptide carriers in rabbit intestinal brush-border membranes: difference of transport characteristics between cefixime and cephradine. J. Pharmacol. Exp. Ther. 247:1988;235-241.
183. Hu M., Subramanian P., Mosberg H.I., Amidon G.L. Use of the peptide carrier system to improve the intestinal absorption of L-α-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-α-methyldopa. Pharm. Res. 6:1989;66-70.
184. Bai J.P.F. pGlu-L-dopa-Pro: Tripeptide prodrug targeting the intestinal peptide transporter for absorption and tissue enzymes for conversion. Pharm. Res. 12:1995;1101-1104.
185. Swaan P.W., Stehouwer M.C., Blok R.I.C., Tukker J.J. Prodrug approaches using the intestinal peptide carrier. Pharm. Res. 10:1993;S-295.
186. Ho N.F.H. Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption. Ann. NY Acad. Sci. 507:1987;315-329.
187. Krag E., Phillips S.F. Active and passive bile acid absorption in man: Perfusion studies of the ileum and jejunum. J. Clin. Invest. 53:1974;1686-1694.
188. Wong M.H., Oelkers P., Craddock A.L., Dawson P.A. Expression cloning and characterization of hamster ileal sodium-dependent bile acid transporter. J. Biol. Chem. 269:1994;1340-1347.
189. Hidalgo I.J., Borchardt R.T. Transport of bile acids in a human intestinal epithelial cell line, Caco-2. Biochim. Biophys. Acta. 1035:1990;97-103.
190. Wilson F.A. Intestinal transport of bile acids. Am. J. Physiol. 241:1981;G83-G92.
191. Buttleworth K.R., Pelley D. Mesentric venous blood sampling in vivo in the rat. J. Physiol. 232:1973;60P-61P.
192. Swaan P.W., Szoka F.C. Jr., Øie S. Use of the intestinal and hepatic bile acid transporters for drug delivery. Adv. Drug Deliv. Rev. 20:1996;59-82.
193. Kramer W., Wess G., Neckermann G., Schubert G., Fink J., Girbig F., Gutjahr U., Kowalewski S., Baringhaus K., Böger G., Enhsen A., Falk E., Friedrich M., Glombik H., Hoffmann A., Pittius C., Urmann M. Intestinal absorption of peptides by coupling to bile acids. J. Biol. Chem. 269:1994;10621-10627.
194. Kim D.C., Harrison A.W., Ruwart M.J., Wilkinson K.F., Fisher J.F., Hidalgo I.J., Borchardt R.T. Evaluation of bile acid transporter in enhancing intestinal permeability to renin-inhibitory peptides. J. Drug Target. 1:1993;347-359.
195. Tamai I., Tsuji A. Carrier-mediated approaches for oral drug delivery. Adv. Drug Deliv. Rev. 20:1996;5-32.
196. Russell-Jones G.J. The potential use of receptor-mediated endocytosis for oral drug delivery. Adv. Drug Deliv. Rev. 20:1996;83-97.
197. Borowitz S.M., Ghishan F.K. Phosphate transport in human jejunal brush-border membrane vesicles. Gastroenterology. 96:1989;4-10.
198. Berner W., Kinne R., Murer H. Phosphate transport into brush-border membrane vesicles isolated from rat small intestine. Biochem. J. 160:1976;467-474.
199. Said H.M., Ghishan F.K., Redha R. Folate transport by intestinal brush-border membrane vesicles. Am. J. Physiol. 252:1987;G229-G236.
200. Said H.M., Redha R. A carrier-mediated transport for folate in basolateral membrane vesicles of rat intestine. Biochem. J. 247:1987;141-146.
201. Tsuji A., Takanaga H., Tamai I., Terasaki T. Transcellular transport of benzoic acid across Caco-2 cells by pH-dependent and carrier-mediated transport mechanism. Pharm. Res. 11:1994;30-37.
202. Takanaga H., Tamai I., Tsuji A. pH-Dependent and carrier-mediated transport of salicylic acid across Caco-2 cells. J. Pharm. Pharmacol. 46:1994;567-570.
203. Saitoh H., Kobayashi M., Sugawara M., Iseki K., Miyazaki K. Carrier-mediated transport system for choline and its related quaternary ammonium compounds on rat intestinal brush-border membrane. Biochim. Biophys. Acta. 1112:1992;153-160.
204. Swaan P., Tukker J.J. Carrier-mediated transport mechanism of foscarnet (trisodium phosphonoformate hexahydrate) in rat intestinal tissue. J. Pharmacol. Exp. Ther. 272:1994;242-247.
205. + and pH-dependent transport of foscarnet via the phosphate carrier system across intestinal brush-border membrane. Biochem. Pharmacol. 38:1989;1019-1022.
206. Ishizawa T., Tsuji A., Tamai I., Terasaki T., Hosoi K., Fukatsu S. Sodium and pH-dependent carrier-mediated transport of antibiotic, fosfomycin, in the rat intestinal brush-border membrane. J. Pharmacobiodyn. 13:1990;292-300.
207. Ishizawa T., Sadahiro S., Hosoi K., Tamai I., Terasaki T., Tsuji A. Mechanisms of intestinal absorption of the antibiotic, fosfomycin, in brush-border membrane vesicles in rabbits and humans. J. Pharmacobiodyn. 15:1992;481-489.
208. Zimmerman J. Methotrexate transport in human intestine. Biochem. Pharmacol. 43:1992;2377-2383.
209. Simanjuntak M.T., Tamai I., Terasaki T., Tsuji A. Carrier-mediated uptake of nicotinic acid by rat intestinal brush-border membrane vesicles and relation to monocarboxylic acid transport. J. Pharmacobiodyn. 13:1990;301-309.